Upon a recent application and discussion with EMA, Cimaas received the classification for its’ dendritic cell vaccine. EMA/CAT considers that the WT1-DC-Xcite-L1 falls within the definitions of a somatic cell therapy medicinal product and a gene therapy medicinal product and based on that is considered as gene therapy medicinal product as provided in Article 2(5)… Read more »
On June 6 2019, Kiadis Pharma (Amsterdam, The Netherlands) acquired Cytosen (USA). CiMaas had a long-standing collaboration with Cytosen to realize production of large numbers of Natural Killer Cells. The acquisition results in that CiMaas will continue the development of the Natural Killer Cell therapy now with Kiadis.
CiMaas will present the company at BIO Capital Europe 2019 in Amsterdam. BIO Capital Europe is a meeting place for investors and life science companies. CiMaas will present its strategy and progress on March 14 at 5 PM.
CiMaas recently applied for a classification for its’ Advanced Therapeutic Medicinal Product, adoptive NK cell therapy for multiple myeloma. Upon this request, the European Medicines Agency / Committee for Advanced Therapies considers that product NK-Xpand-MM1 falls within the definition of somatic cell therapy medicinal product, as provided in Article 2 of Regulation (EC) No 1394/2007. This… Read more »
Mercurius Heerlen B.V. and Werker Beleggingsmaatschappij B.V. invested a second round in CiMaas B.V. to realize cancer immunotherapy.This brings CiMaas again a step closer to fund its’ development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer.
Mr Alexander Vos joined the Supervisory Board of CiMaas in May 2018. Alexander Vos is the former CEO of PharmaCell BV, based in Maastricht and Geleen.
CiMaas announced the granting of a European Patent on its Dendritic Cells maturation technology, an essential part of its Dendritic Cell Vaccine Product.
CiMaas moves it’s clinical production site to InSciTe in Sittard-Geleen. Working together in the Biomedical Accelerator Matrix, CiMaas and InSciTe are joining forces to bring a cure for cancer one step closer to reality.
MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V. invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.
The province of Limburg, through LBDF, has awarded CiMaas a subsidy for further development of the new technology for large scale production of NK cell immunotherapy. Under the subsidy, CiMaas collaborates with the department of Haematology of the MUMC+ and an American biotech company to further optimize the treatment.